Compare Aecom (ACM) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aecom vs Crispr Therapeutics AG — how do they compare? Aecom trades at $66.97 (market cap $8.62B), while Crispr Therapeutics AG trades at $53.96 (market cap $5.23B). The key difference: Aecom is the larger of the two by market cap, and Aecom pays a 1.77% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| ACM | CRSP | |
|---|---|---|
Market Cap | $8.62B | $5.23B |
Sector | Industrials | Health |
52-Week High | $134.35 | $76.78 |
52-Week Low | $66.86 | $44.34 |
Enterprise Value | $10.81B | $3.65B |
Dividend Yield | 1.77% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Aecom
Aecom is one of the largest global providers of design, engineering, construction, and management services. The firm serves a broad spectrum of end markets including infrastructure, water, transportation, and energy. Based in Los Angeles, Aecom has a presence in over 150 countries and employs 51,000. The company generated $13.3 billion in sales and $701 million in adjusted operating income in fiscal 2021.
Read more on ACM →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
